Literature DB >> 23413226

Hybrid perventricular device closure of doubly committed subarterial ventricular septal defects: mid-term results.

Ke Lin1, Da Zhu, Kaiyu Tao, Changping Gan, Hong Tang, Yuan Feng, Qi An.   

Abstract

BACKGROUND: Doubly committed Subarterial ventricular septal defect (VSD) is a specific anatomic type of VSD located just beneath the aortic valve. The purpose of this study was to evaluate the safety and feasibility of using minimal invasive perventricular device closure in managing this type of VSD.
METHODS: During Dec 2008 and Aug 2010, 34 Pediatric patients with doubly committed subarterial VSD who met the inclusion criteria for device closure were enrolled in this study. Perventricular closure was attempted using a unique design eccentric device under the guidance of real-time transesophageal echocardiography. Complications such as residual shunt, valve regurgitation, arrhythmias were all recorded in postoperative period and during follow-up. RESULT: Perventricular device closure was successfully done in 28 patients (82%). 6 patients converted to open surgical repair due to residual shunt >3mm (1 patient), more than mild degree aortic regurgitation (3 patients) and device mal-position (2 patients). Complete closure rate was achieved in 93% at discharge and 100% during 20 months follow-up. No severe complications such as device embolism, significant arrhythmias and noticeable valve regurgitation were noted during follow-up. Procedure induced trivial grade aortic valve regurgitation was noted in five (18%) patients after procedure while only one (4%) persisted during midterm follow-up.
CONCLUSION: Perventricular closure of doubly committed subarterial VSDs appears to be a safe and effective minimally invasive technique with good mid-term outcomes.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  congenital heart defect; doubly committed subarterial ventricular septal defect; perventricular device closure

Mesh:

Year:  2013        PMID: 23413226     DOI: 10.1002/ccd.24869

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  7 in total

1.  Minimally invasive perventricular device closure of doubly committed sub-arterial ventricular septal defects: single center long-term follow-up results.

Authors:  Shu Zhang; Da Zhu; Qi An; Hong Tang; Dajiang Li; Ke Lin
Journal:  J Cardiothorac Surg       Date:  2015-09-15       Impact factor: 1.637

2.  Minimally access via left anterior mini-thoracotomy for repair of adult subarterial ventricular septal defects.

Authors:  YunFei Liao; Xiang Long; ShuQiang Zhu; Jun Tu; Hua Wen; JianJun Xu; YongBing Wu
Journal:  J Cardiothorac Surg       Date:  2017-06-12       Impact factor: 1.637

3.  Effects of transthoracic device closure on ventricular septal defects and reasons for conversion to open-heart surgery: A meta-analysis.

Authors:  Yang Zhou; Ling-Xi Liu; Fei Zhao; Shi-Hai Tang; Hua-Li Peng; Yun-Han Jiang
Journal:  Sci Rep       Date:  2017-09-22       Impact factor: 4.379

4.  A meta-analysis of perventricular device closure of doubly committed subarterial ventricular septal defects.

Authors:  Jiang-Shan Huang; Kai-Peng Sun; Shu-Ting Huang; Qiang Chen; Liang-Wan Chen; Yur-Ren Kuo
Journal:  J Cardiothorac Surg       Date:  2020-01-28       Impact factor: 1.637

5.  Percutaneous-perventricular device closure of ventricular septal defect: mid-term follow-up.

Authors:  Long Wang; Lin Xie; Weiqiang Ruan; Tao Li; Changping Gan; Ke Lin
Journal:  BMC Surg       Date:  2020-09-18       Impact factor: 2.102

6.  Transfemoral Occlusion of Doubly Committed Subarterial Ventricular Septal Defect Using the Amplatzer Duct Occluder-II in Children.

Authors:  Changqing Tang; Kaiyu Zhou; Shuran Shao; Xiaoliang Liu; Yifei Li; Yimin Hua; Chuan Wang
Journal:  Front Cardiovasc Med       Date:  2022-04-12

Review 7.  Recent advances in managing septal defects: ventricular septal defects and atrioventricular septal defects.

Authors:  P Syamasundar Rao; Andrea D Harris
Journal:  F1000Res       Date:  2018-04-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.